Medical Marijuana, Inc, parent company of Kannaway, is launching a rebranding of its subsidiary HempMeds. This change comes as part of the company’s recent shift in consumer strategy and executive leadership.
“As the CBD industry continues to expand exponentially throughout the world, especially in the US and Latin America, we saw an opportunity to further leverage Raul Elizalde’s tremendous experience in the CBD industry by positioning him as the sole CEO of HempMeds,” says HempMeds® Co-Founder Michelle Sides. “This is an exciting new direction for the company which comes with new initiatives and activities such as updated branding, new products and digital events in 2021. We are confident that consumers will respond positively to the new HempMeds branding as we continue pushing the industry forward as [we] have since founding the company to help trailblaze the CBD market many years ago.”
Included in this rebranding strategy is a new website, updated logos, refreshed packaging, new product formulations for its RSHO® product line and the unveiling of two new products, one containing cannabigerol (CBG) and the other cannabinol (CBN).
“After many years of fighting for broadened access to CBD around the globe, cannabinoids have finally been accepted into mainstream culture in the U.S. and other countries around the world,” says HempMeds® CEO Raul Elizalde. “With this rebranding, we aim to show that we are constantly changing to match the world’s shift toward CBD and that our products are meant for use by all consumers while maintaining our high quality.”
HempMeds® will also be selecting members for its Medical Advisory Board to serve as advisors during the company’s expansion.